| Vinpocetine |
20010063 |
Vinpocetine Covex, Tablet, 5, mg, Pack: 25 |
Covex S.A., Испания |
Kern Pharma S.L. Spain |
2.03 |
0.41 |
2.44 |
7% |
0.14 |
2.17 |
0.43 |
2.6 |
20% |
0.41 |
2.58 |
0.52 |
3.1 |
КЦPP-515/19.04.2012 промяна на обстоятелства; НСР-14800/10.01.2018 |
КЦ-341/17.12.2008 |
12.01.2009 |
02.02.2018 |
Неактивен |
320 |
| Vinpocetine |
ІІ-12901/28.04.2006 г. |
Vinpocetine Covex, Tablet, 5, mg, Pack: 25 |
Covex S.A., Испания |
Kern Pharma S.L. Spain |
2.03 |
0.41 |
2.44 |
7% |
0.14 |
2.17 |
0.43 |
2.6 |
20% |
0.41 |
2.58 |
0.52 |
3.1 |
КЦPP-515/19.04.2012 промяна на обстоятелства |
КЦ-341/17.12.2008 |
12.01.2009 |
12.01.2009 |
Неактивен |
320 |
| Nevirapine |
EU/1/97/055/003 |
VIRAMUNE, Tablet, 200, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co.KG, Germany; Boehringer Ingelheim Ellas A.E., Greece |
271.7 |
54.34 |
326.04 |
4% |
10 |
281.7 |
56.34 |
338.04 |
16% |
25 |
306.7 |
61.34 |
368.04 |
цената се заличава HCР-500/11.07.2013 |
НСР-23/03.06.2013 |
26.06.2013 |
26.06.2013 |
Заличен |
1864 |
| Nevirapine |
EU/1/97/055/003 |
VIRAMUNE, Tablet, 200, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co.KG, Germany; Boehringer Ingelheim Ellas A.E., Greece |
273.23 |
54.65 |
327.88 |
4% |
10 |
283.23 |
56.65 |
339.88 |
16% |
25 |
308.23 |
61.65 |
369.88 |
|
КЦРР-1122/02.08.2012 |
17.08.2012 |
17.08.2012 |
Неактивен |
1864 |
| Nevirapine |
EU/1/97/055/003 |
VIRAMUNE, Tablet, 200, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co.KG, Germany; Boehringer Ingelheim Ellas A.E., Greece |
281.46 |
56.29 |
337.75 |
6% |
15 |
296.46 |
59.29 |
355.75 |
18% |
30 |
326.46 |
65.29 |
391.75 |
|
КЦ-585/23.02.2009 |
18.03.2009 |
18.03.2009 |
Неактивен |
1864 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences Ireland UC, Ирландия |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH, Germany |
265.7 |
53.14 |
318.84 |
4% |
10 |
275.7 |
55.14 |
330.84 |
16% |
25 |
300.7 |
60.14 |
360.84 |
корекционно решение НСР-12037/20.03.2017; Промяна на обстоятелства-НСР-17897/07.02.2019 |
НСР-7692/10.12.2015.; НСР-11691/10.02.2017; НСР-14677/20.12.2017; НСР-16684/30.08.2018 |
14.09.2018 |
02.03.2019 |
Активен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH, Germany |
265.7 |
53.14 |
318.84 |
4% |
10 |
275.7 |
55.14 |
330.84 |
16% |
25 |
300.7 |
60.14 |
360.84 |
корекционно решение НСР-12037/20.03.2017 |
НСР-7692/10.12.2015.; НСР-11691/10.02.2017; НСР-14677/20.12.2017; НСР-16684/30.08.2018 |
14.09.2018 |
02.10.2018 |
Неактивен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH, Germany |
465.47 |
93.09 |
558.56 |
4% |
10 |
475.47 |
95.09 |
570.56 |
16% |
25 |
500.47 |
100.09 |
600.56 |
корекционно решение НСР-12037/20.03.2017 |
НСР-7692/10.12.2015.; НСР-11691/10.02.2017; НСР-14677/20.12.2017 |
06.01.2018 |
02.02.2018 |
Неактивен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH, Germany |
469.09 |
93.82 |
562.91 |
4% |
10 |
479.09 |
95.82 |
574.91 |
16% |
25 |
504.09 |
100.82 |
604.91 |
корекционно решение НСР-12037/20.03.2017 |
НСР-7692/10.12.2015.; НСР-11691/10.02.2017 |
25.02.2017 |
02.05.2017 |
Неактивен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH, Germany |
469.09 |
93.82 |
562.91 |
4% |
10 |
479.09 |
95.82 |
574.91 |
16% |
25 |
504.09 |
100.82 |
604.91 |
|
НСР-7692/10.12.2015.; НСР-11691/10.02.2017 |
02.03.2017 |
02.03.2017 |
Неактивен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH , Germany |
472.14 |
94.43 |
566.57 |
4% |
10 |
482.14 |
96.43 |
578.57 |
16% |
25 |
507.14 |
101.43 |
608.57 |
|
НСР-7692/10.12.2015. |
26.12.2015 |
26.12.2015 |
Неактивен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH , Germany |
477.12 |
95.42 |
572.54 |
4% |
10 |
487.12 |
97.42 |
584.54 |
16% |
25 |
512.12 |
102.42 |
614.54 |
|
НСР-5914/27.03.2015 |
10.04.2015 |
10.04.2015 |
Неактивен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH , Germany |
479.8 |
95.96 |
575.76 |
4% |
10 |
489.8 |
97.96 |
587.76 |
16% |
25 |
514.8 |
102.96 |
617.76 |
|
НСР-2191/20.12.2013 |
23.01.2014 |
23.01.2014 |
Неактивен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH , Germany |
489.88 |
97.98 |
587.86 |
4% |
10 |
499.88 |
99.98 |
599.86 |
16% |
25 |
524.88 |
104.98 |
629.86 |
|
КЦРР-568/04.05.2012 ; КЦРР-936/16.07.2012 |
06.03.2013 |
06.03.2013 |
Неактивен |
3712 |
| Tenofovir disoproxil |
EU/1/01/200/001 |
Viread, Film coated tablet, 245, mg, Pack: 30 |
Gilead Sciences International Ltd., Обединено Кралство |
Gilead Sciences Limited Ltd, Ireland; Altana Pharma Oranienburger GmbH , Germany |
560.81 |
112.16 |
672.97 |
4% |
10 |
570.81 |
114.16 |
684.97 |
16% |
25 |
595.81 |
119.16 |
714.97 |
|
КЦ-387/07.01.2009 |
27.01.2009 |
27.01.2009 |
Неактивен |
3712 |
| Tenofovir disoproxil |
20180079 |
Virofob, Film coated tablet, 245, mg, Pack: 30 |
Alvogen Malta Operations (ROW) Ltd., Малта |
Remedica Ltd, Кипър |
129.59 |
25.92 |
155.51 |
4% |
5.18 |
134.77 |
26.95 |
161.72 |
16% |
20.73 |
155.5 |
31.1 |
186.6 |
|
НСР-17143/01.11.2018 |
16.11.2018 |
02.12.2018 |
Активен |
16338 |
| Dienogest |
20100101 |
Visanne, Tablet, 2 mg, -, Pack: 28 |
Bayer Pharma AG, Германия |
Bayer Weimar GmbH und Co.KG |
58.13 |
11.63 |
69.76 |
4% |
2.33 |
60.46 |
12.09 |
72.55 |
16% |
9.3 |
69.76 |
13.95 |
83.71 |
Цената e вписана в регистъра на пределните цени с решение НСР-5199/04.12.2014 |
НСР-4608/15.09.2014 |
30.09.2014 |
30.09.2014 |
Заличен |
3192 |
| Dienogest |
20100101 |
Visanne, Tablet, 2 mg, -, Pack: 28 |
Bayer Pharma AG, Германия |
Bayer Weimar GmbH und Co.KG |
65.36 |
13.07 |
78.43 |
4% |
2.61 |
67.97 |
13.59 |
81.56 |
16% |
10.46 |
78.43 |
15.69 |
94.12 |
промяна на обстоятелства НСР-2660/03.02.2014 |
НСР-2300/13.01.2014 |
28.01.2014 |
28.01.2014 |
Неактивен |
3192 |
| Dienogest |
20100101 |
Visanne, Tablet, 2 mg, -, Pack: 28 |
Bayer Schering Pharma AG,, Германия |
Bayer Weimar GmbH und Co.KG |
66.5 |
13.3 |
79.8 |
4% |
2.66 |
69.16 |
13.83 |
82.99 |
16% |
10.64 |
79.8 |
15.96 |
95.76 |
|
КЦРР-2434/22.02.2013 |
21.03.2013 |
21.03.2013 |
Неактивен |
3192 |
| Iodixanol |
ІІ-14561/19.10.2006 |
Visipaque, Solution for injection, 320 mg I/ ml-100 ml, mg, Pack: 10 |
GE Healthcare AS, Норвегия |
GE Healthcare AS; GE Healthcare Ireland |
393.55 |
78.71 |
472.26 |
4% |
10 |
403.55 |
80.71 |
484.26 |
16% |
25 |
428.55 |
85.71 |
514.26 |
Жалбата е върната като нередовна от Комисия по прозрачност с решение КП-44/05.03.2015 |
НСР-3670/06.06.2014 |
02.04.2015 |
02.04.2015 |
Активен |
3671 |
| Iodixanol |
ІІ-14561/19.10.2006 |
Visipaque, Solution for injection, 320 mg I/ ml-100 ml, mg, Pack: 10 |
GE Healthcare AS, Норвегия |
GE Healthcare AS; GE Healthcare Ireland |
606.7 |
121.34 |
728.04 |
4% |
10 |
616.7 |
123.34 |
740.04 |
16% |
25 |
641.7 |
128.34 |
770.04 |
|
КЦРР-2209/06.02.2013 |
03.04.2013 |
03.04.2013 |
Неактивен |
3671 |
| Iodixanol |
ІІ-14561/19.10.2006 |
Visipaque, Solution for injection, 320 mg I/ ml-50 ml, mg, Pack: 10 |
GE Healthcare AS, Норвегия |
GE Healthcare AS; GE Healthcare Ireland |
196.89 |
39.38 |
236.27 |
4% |
7.88 |
204.77 |
40.95 |
245.72 |
16% |
25 |
229.77 |
45.95 |
275.72 |
Цената е вписана в регистъра на пределните цени с решение НСР-4688/25.09.2014 (в сила от 16.10.2014); Върната като нередовна жалбата от Комисия по прозрачност с решение КП-44/05.03.2015 и НСР-3670/06.06.2014 |
КЦРР-2209/06.02.2013 |
03.04.2013 |
03.04.2013 |
Заличен |
1748 |
| Iodixanol |
ІІ-14561/19.10.2006 |
Visipaque, Solution for injection, 320 mg I/ ml-20 ml, mg, Pack: 10 |
GE Healthcare AS, Норвегия |
GE Healthcare AS; GE Healthcare Ireland |
115.94 |
23.19 |
139.13 |
4% |
4.64 |
120.58 |
24.12 |
144.7 |
16% |
18.55 |
139.13 |
27.83 |
166.96 |
Цената е вписана в регистъра на пределните цени с решение НСР-4688/25.09.2014 (в сила от 16.10.2014) |
КЦРР-2209/06.02.2013 |
03.04.2013 |
03.04.2013 |
Заличен |
1747 |
| Iodixanol |
ІІ-14561/19.10.2006 |
Visipaque, Solution for injection, 320 mg I/ ml-100 ml, mg, Pack: 10 |
GE Healthcare AS, Норвегия |
GE Healthcare AS
GE Healthcare Ireland |
899.68 |
179.94 |
1079.62 |
4% |
10 |
909.68 |
181.94 |
1091.62 |
16% |
25 |
934.68 |
186.94 |
1121.62 |
|
КЦ-823/15.04.2009 |
30.04.2009 |
30.04.2009 |
Неактивен |
3671 |
| Iodixanol |
ІІ-14561/19.10.2006 |
Visipaque, Solution for injection, 320 mg I/ ml-20 ml, mg, Pack: 10 |
GE Healthcare AS, Норвегия |
GE Healthcare AS
GE Healthcare Ireland |
252.3 |
50.46 |
302.76 |
4% |
10 |
262.3 |
52.46 |
314.76 |
16% |
25 |
287.3 |
57.46 |
344.76 |
|
КЦ-823/15.04.2009 |
30.04.2009 |
30.04.2009 |
Неактивен |
1747 |